Company Registration No. 03567687 (England and Wales)
Inpharmation Limited
Unaudited accounts
for the year ended 31 March 2026
Inpharmation Limited
Unaudited accounts
Contents
Inpharmation Limited
Company Information
for the year ended 31 March 2026
Directors
Gary Anthony Johnson
Karen Johnson
Samuel James Johnson
Kim Hardy Robinson
Nicholas Taylor
Robert Watson
Company Number
03567687 (England and Wales)
Registered Office
Evidence House
Stokenchurch Business Park Ibstone Road
Stokenchurch
HP14 3FE
United Kingdom
Accountants
James Norman Business Advisory Limited
27 Sheet Street
Windsor
SL4 1BN
Inpharmation Limited
Statement of financial position
as at 31 March 2026
Intangible assets
12,188
12,188
Tangible assets
2,068,014
1,928,901
Cash at bank and in hand
2,941,326
3,673,450
Creditors: amounts falling due within one year
(774,676)
(841,130)
Net current assets
3,226,088
3,512,017
Total assets less current liabilities
5,306,290
5,453,106
Provisions for liabilities
Deferred tax
(6,885)
(14,794)
Net assets
5,299,405
5,438,312
Called up share capital
105
105
Capital redemption reserve
1
1
Profit and loss account
5,299,299
5,438,206
Shareholders' funds
5,299,405
5,438,312
For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 12 October 2026 and were signed on its behalf by
Karen Johnson
Director
Company Registration No. 03567687
Inpharmation Limited
Notes to the Accounts
for the year ended 31 March 2026
Inpharmation Limited is a private company, limited by shares, registered in England and Wales, registration number 03567687. The registered office is Evidence House, Stokenchurch Business Park Ibstone Road, Stokenchurch, HP14 3FE, United Kingdom.
These financial statements have been prepared in compliance with FRS 102, ’The Financial Reporting Standard applicable to the UK and Republic of Ireland’ including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
The accounts are presented in £ sterling.
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
The patents and licences are not currently being amortised.
Tangible fixed assets and depreciation
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Land & buildings
2% Straight Line
Plant & machinery
20% Reducing Balance
Motor vehicles
20% Reducing Balance
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
Current or deferred taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Inpharmation Limited
Notes to the Accounts
for the year ended 31 March 2026
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.
Expenditure on research and development is written off in the year in which it is incurred.
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
3
Intangible fixed assets
Other
4
Tangible fixed assets
Land & buildings
Plant & machinery
Motor vehicles
Total
Cost or valuation
At cost
At cost
At cost
At 1 April 2025
2,146,027
289,467
53,315
2,488,809
Additions
175,749
3,546
28,653
207,948
Disposals
-
-
(26,078)
(26,078)
At 31 March 2026
2,321,776
293,013
55,890
2,670,679
At 1 April 2025
286,328
241,919
31,661
559,908
Charge for the year
46,436
9,670
2,231
58,337
On disposals
-
-
(15,580)
(15,580)
At 31 March 2026
332,764
251,589
18,312
602,665
At 31 March 2026
1,989,012
41,424
37,578
2,068,014
At 31 March 2025
1,859,699
47,548
21,654
1,928,901
Inpharmation Limited
Notes to the Accounts
for the year ended 31 March 2026
Amounts falling due within one year
Trade debtors
720,481
508,664
Accrued income and prepayments
46,523
21,709
Other debtors
292,434
149,324
6
Creditors: amounts falling due within one year
2026
2025
Trade creditors
12,723
19,231
Taxes and social security
66,815
62,747
Other creditors
64,344
68,191
Loans from directors
9,304
8,477
Allotted, called up and fully paid:
105 Ordinary shares of £1 each
105
105
8
Average number of employees
During the year the average number of employees was 42 (2025: 39).